שווי פעילות לרווח לפני ריבית, מסים ופחת Indaptus Therapeutics, Inc. (INDP)

Indaptus Therapeutics (INDP) aims for the global implementation of its Decoy platform, which activates anti-tumor immunity via bacterial components. This chart of EV/EBITDA price action, with a value of 0.00, reflects operations within the biopharmaceuticals and oncology center segment, where profits are generated through innovative therapy methods. The stability of business processes is ensured by the reliability of high-precision equipment and strict adherence to schedules at partner manufacturing plants.

For the capital-intensive Indaptus Therapeutics (INDP), the EV/EBITDA multiple serves as a tool for valuing the business by accounting for net debt relative to operating profit. This metric compares the total market value of the asset with its ability to generate cash flow before taxes, depreciation, and amortization. By analyzing the EV/EBITDA trend, an investor can assess the company's resilience amid geopolitical risks that are hindering the international registration of immunotherapy drugs.